Pancreatic cancer, to this day, is still one of the most lethal solid tumors. Despite decades of research, it remains the fourth leading cause of cancer-related death worldwide, with a five-year survival rate of less than 9%. Without treatment, the median survival time is consistently shorter than six months. Part of the reason for this poor prognosis is due to limited screening methodologies causing pancreatic cancer patients to be diagnosed with the late-stage disease at initial presentation. Further reasons include the complex and high-risk surgical procedures and the high rate of chemoresistance and recurrence.
Non-metastatic pancreatic cancer can be classified into 3 groups: resectable, borderline resectable and locally advanced pancreatic cancer (LAPC). Only 10–20% of patients are eligible for surgery, and approximately 30% are diagnosed as LAPC. Currently, the role of radiation therapy is controversial in patients with resectable Pancreatic Cancer due to the lack of definitive data evaluating the use of adjuvant therapy using modern radiotherapy techniques. In order to improve the prognosis for pancreatic cancer patient, further research into the optimal radiotherapy fractionation schedule and the total dose is necessary.
This Research Topic aims to provide updates on radiotherapy in the treatment of Pancreatic Cancer. We encourage submissions that focus on, but not limited to, the following themes:
- Delivery techniques for Pancreatic Cancer in particular SBRT
- Updates in chemoradiotherapy for Pancreatic Cancer
- Motion Management of Pancreatic Cancer
- Adverse effects of Radiotherapy for Pancreatic Cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Pancreatic cancer, to this day, is still one of the most lethal solid tumors. Despite decades of research, it remains the fourth leading cause of cancer-related death worldwide, with a five-year survival rate of less than 9%. Without treatment, the median survival time is consistently shorter than six months. Part of the reason for this poor prognosis is due to limited screening methodologies causing pancreatic cancer patients to be diagnosed with the late-stage disease at initial presentation. Further reasons include the complex and high-risk surgical procedures and the high rate of chemoresistance and recurrence.
Non-metastatic pancreatic cancer can be classified into 3 groups: resectable, borderline resectable and locally advanced pancreatic cancer (LAPC). Only 10–20% of patients are eligible for surgery, and approximately 30% are diagnosed as LAPC. Currently, the role of radiation therapy is controversial in patients with resectable Pancreatic Cancer due to the lack of definitive data evaluating the use of adjuvant therapy using modern radiotherapy techniques. In order to improve the prognosis for pancreatic cancer patient, further research into the optimal radiotherapy fractionation schedule and the total dose is necessary.
This Research Topic aims to provide updates on radiotherapy in the treatment of Pancreatic Cancer. We encourage submissions that focus on, but not limited to, the following themes:
- Delivery techniques for Pancreatic Cancer in particular SBRT
- Updates in chemoradiotherapy for Pancreatic Cancer
- Motion Management of Pancreatic Cancer
- Adverse effects of Radiotherapy for Pancreatic Cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.